Back to search results

Targeted Accelerated TMS for Post-Traumatic Stress Disorder

This study is testing a new way to deliver Transcranial Magnetic Stimulation (TMS) called accelerated intermittent theta burst stimulation (aiTBS) for people with Post-Traumatic Stress Disorder (PTSD). TMS is a non-invasive (doesn't break the skin) brain stimulation procedure that is already approved for depression. Researchers want to see if this accelerated TMS, which is given over a shorter time, can help improve PTSD symptoms. You might be able to join if you are 18-65 years old, have a PTSD diagnosis, and have at least moderate PTSD symptoms. The study will measure success by how much your PTSD symptoms improve after treatment. The current status of this study is unclear, and it plans to enroll 40 participants.

Study design
This is an interventional study planning to enroll 40 participants. The study will use a randomized controlled design, meaning participants will be assigned to different groups by chance.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your PTSD symptoms will be measured from before treatment up to one month after treatment ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07245641

Targeted Accelerated TMS for Post-Traumatic Stress Disorder

Recruiting
NAAges 18–65InterventionalTreatment
Brigham and Women's Hospital
~40 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:Transcranial Magnetic Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PTSD Checklist with Criterion A for DSM-5 (PCL-5)
Measured over Before treatment to 1-month post treatment

Conditions

Post Traumatic Stress Disorder (PTSD)

Explore related trials

Post-Traumatic Stress Disorder

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Interventional Psychiatry Research Group
[email protected]
6175253526
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-65
DSM-5 diagnosis of PTSD per PTSD Checklist for DSM-5 (CAPS-5)
At least moderate symptoms of PTSD per PCL-5 (≥21)
English proficiency sufficient to understand risks/benefits
No new medications or medication increases before, during, or after aTMS
Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial
Agreement to lifestyle considerations:
Abstain from becoming pregnant from screening to one-month after treatment (the MRI visit)
Continue usual intake patterns of caffeine- or xanthine-containing products (e.g. coffee, tea, soft drinks, chocolate) throughout treatment
No changes to routine intake of alcohol, tobacco, and recreational drugs if patients are using them at baseline for at least 24 hours before the start of each MRI and TMS session

What this trial measures

  • PTSD Checklist with Criterion A for DSM-5 (PCL-5)Before treatment to 1-month post treatment

    20 item PTSD scale, scored 0-80. Higher scores indicate worse symptoms. Investigators will use a repeated measures mixed model to examine the effect of treatment on PCL-5 scores over time as well as a group x time interaction not controlling for depression. Hypothesis: There will be a significant difference in PCL-5 score magnitude of change one month after treatment relative to baseline in the participants receiving active treatment vs. sham